ProLog Pharma Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The notice of the 18th meeting of the 9th Board of Directors was sent on February 28, 2026, via SMS and email. The meeting was held on March 10, 2026, in the first-floor conference room of the Company, combining "on-site + communication" methods, and was presided over by Chairman Mr. Zhu Fangmeng. A total of 9 directors were supposed to attend, and all 9 directors were present, along with some senior executives of the Company. The meeting complied with the relevant provisions of the Company Law and the Articles of Association.
After deliberation and voting by the attending directors, the following resolutions were passed:
- Review and Approval of the Proposal on the Draft and Summary of the 2026 Stock Option Incentive Plan
To further establish and improve the Company's long-term incentive mechanism, attract and retain outstanding talent, and fully mobilize the enthusiasm of core management and technical personnel, the Company has drafted the "2026 Stock Option Incentive Plan (Draft)" and its summary.
Voting results: 9 votes in favor, 0 votes against, 0 abstentions. This proposal is subject to review by the Company's shareholders' meeting.